Blood Pressure and Brain Blood Flow Regulation After Midodrine Administration in Those With Spinal Cord Injury
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01498809 |
Recruitment Status
:
Completed
First Posted
: December 23, 2011
Last Update Posted
: March 17, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Orthostatic Intolerance | Drug: Midodrine |
Study Type : | Observational |
Actual Enrollment : | 22 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Neural and Mechanical Baroreflex Sensitivity and Cerebral Blood Flow |
Study Start Date : | March 2012 |
Actual Primary Completion Date : | November 2013 |
Actual Study Completion Date : | November 2013 |

-
Drug: Midodrine
- Baroreflex sensitivity [ Time Frame: Immediately after drug administration (30 mins) ]
- Cerebral autoregulation [ Time Frame: Thirty minutes after administration ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 49 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- To be included in the study, participants must have sustained a traumatic spinal cord injury within the ages of 18-49 years.
- Also, participants must have an injury level above the 6th thoracic vertebrae and be a non-smoker for a minimum of one year.
Exclusion Criteria:
- Any participants with a history of cardiovascular disease, pulmonary disease or diabetes mellitus will not be eligible.
- Also, participants will not be eligible to take part in study if they experiences acute distress, or are taking medications known to influence cardiovascular function.
- Patient will be not eligible for the study if he/she has known adverse reaction to Midodrine.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01498809
Canada, British Columbia | |
GF Strong Hospital and Rehabilitation Centre | |
Vancouver, British Columbia, Canada, V5Z 2G9 |
Principal Investigator: | Darren Warburton, PhD | University of British Columbia | |
Principal Investigator: | Andrei Krassioukov, MD PhD | GF Strong Hospital University of British Columbia |
Responsible Party: | University of British Columbia |
ClinicalTrials.gov Identifier: | NCT01498809 History of Changes |
Other Study ID Numbers: |
H11-02823 |
First Posted: | December 23, 2011 Key Record Dates |
Last Update Posted: | March 17, 2014 |
Last Verified: | March 2014 |
Keywords provided by University of British Columbia:
Orthostatic intolerance in people with spinal cord injury |
Additional relevant MeSH terms:
Spinal Cord Injuries Orthostatic Intolerance Spinal Cord Diseases Central Nervous System Diseases Nervous System Diseases Trauma, Nervous System Wounds and Injuries Primary Dysautonomias Autonomic Nervous System Diseases Neurologic Manifestations Signs and Symptoms Midodrine |
Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Vasoconstrictor Agents Adrenergic alpha-1 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |